JNJ

MKT CAP:$550B

Johnson & Johnson

Market Cap

$550B

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NYSE

Healthcare·Drug Mfg.·🇺🇸·NYSE

Stock Price

$227.92+$20.57 (+9.92%)

Apr 24, 2026

Company Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to foc...

CEO

Joaquin Duato

IPO Date

Jan 2, 1943

Website

www.jnj.com

Key Metrics TTM

Revenue

$96.7B

+6.7% YoY

Net Income

$20.7B

EPS (Diluted)

$8.50

Free Cash Flow

$17.8B

Revenue / Share

$39.54

Gross Margin

70.0%

Operating Margin

26.4%

Net Margin

21.4%

FCF Margin

18.4%

P/S

5.7x

P/E

26.5x

Earnings Reports

Q1 2026

Apr 22, 2026

NEW

$24.1B+9.9%EPS $2.14

FY 2025

Feb 11, 2026

$94.2B+6.0%EPS $11.03

Q4 2025

Feb 11, 2026

$24.6B+9.1%EPS $2.10

Q3 2025

Oct 22, 2025

$24.0B+6.8%EPS $2.12

Q2 2025

Jul 24, 2025

$23.7B+5.8%EPS $2.29

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$23.4B	$15.8B	$6.1B
Q2 22	$24.0B	$16.1B	$6.5B
Q3 22	$20.0B	$13.8B	$5.7B
Q4 22	$23.7B	$15.9B	$3.9B
Q1 23	$20.9B	$14.2B	$6.2B
Q2 23	$21.5B	$15.1B	$6.4B
Q1 24	$21.4B	$14.9B	$6.3B
Q2 24	$22.4B	$15.6B	$6.7B
Q3 24	$22.5B	$15.5B	$5.3B
Q4 24	$22.5B	$15.4B	$3.8B
Q1 25	$21.9B	$14.5B	$6.3B
Q2 25	$23.7B	$16.1B	$6.8B
Q3 25	$24.0B	$16.7B	$7.1B
Q4 25	$24.6B	$16.6B	$5.6B
Q1 26	$24.1B	$17.2B	$6.4B
Q1 26	$24.1B	$17.2B	$6.4B

Valuation

Quarter	P/S	P/E
Q1 22	4.9x	23.4x
Q2 22	5.0x	26.1x
Q3 22	4.6x	22.3x
Q4 22	5.0x	25.5x
Q1 23	4.6x	32.0x
Q2 23	4.8x	31.6x
Q1 24	4.3x	32.0x
Q2 24	4.1x	27.1x
Q3 24	4.4x	24.7x
Q4 24	3.9x	24.5x
Q1 25	4.5x	18.4x
Q2 25	4.1x	16.4x
Q3 25	4.8x	17.6x
Q4 25	5.4x	18.8x
Q1 26	6.1x	28.0x
Q1 26	6.1x	28.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	$5.7B	$4.3B
Q1 22	$4.0B	$3.4B
Q2 22	$5.6B	$4.7B
Q3 22	$6.3B	$5.3B
Q4 22	$5.3B	$3.8B
Q1 23	$3.3B	$2.4B
Q2 23	$4.2B	$3.1B
Q1 24	$3.7B	$2.9B
Q2 24	$5.6B	$4.7B
Q3 24	$8.0B	$5.7B
Q4 24	$7.0B	$4.8B
Q1 25	$4.2B	$3.4B
Q2 25	$3.9B	$2.5B
Q3 25	$9.2B	$8.4B
Q4 25	$7.3B	$5.5B
Q1 26	$2.5B	$1.5B

Capital Expenditures

Quarter	CapEx
Q4 21	$1.4B
Q1 22	$607M
Q2 22	$863M
Q3 22	$952M
Q4 22	$1.6B
Q1 23	$863M
Q2 23	$1.1B
Q1 24	$807M
Q2 24	$976M
Q3 24	$2.3B
Q4 24	$2.1B
Q1 25	$809M
Q2 25	$1.4B
Q3 25	$788M
Q4 25	$1.8B
Q1 26	$1.0B

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+5.0%	+11.9%
Q2 22	+3.0%	+3.5%
Q3 22	-14.3%	-13.0%
Q4 22	-4.4%	-2.6%
Q1 23	-10.8%	-15.4%
Q2 23	-10.4%	-13.6%
Q1 24	+6.9%	+5.4%
Q2 24	-5.3%	-20.3%
Q3 24	+7.5%	+17.4%
Q4 24	+4.7%	+23.2%
Q1 25	+2.4%	+3.2%
Q2 25	+5.8%	+7.2%
Q3 25	+6.8%	-1.7%
Q4 25	+9.1%	+1.6%
Q1 26	+9.9%	+13.3%
Q1 26	+1.3%	+4.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$215M	0.9%
Q1 22	$278M	1.2%
Q2 22	$366M	1.5%
Q3 22	$281M	1.4%
Q4 22	$213M	0.9%
Q1 23	$306M	1.5%
Q2 23	$382M	1.8%
Q1 24	$302M	1.4%
Q2 24	$341M	1.5%
Q3 24	$295M	1.3%
Q4 24	$238M	1.1%
Q1 25	$288M	1.3%
Q2 25	$410M	1.7%
Q3 25	$347M	1.4%
Q4 25	$309M	1.3%
Q1 26	$300M	1.2%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$4.1B	$5.6B	—
Q2 22	$3.7B	$5.9B	—
Q3 22	$3.5B	$4.7B	—
Q4 22	$4.6B	$7.4B	—
Q1 23	$3.5B	$4.5B	—
Q2 23	$3.7B	$5.0B	—
Q1 24	$3.5B	$5.1B	—
Q2 24	$3.4B	$5.5B	—
Q3 24	$5.0B	$5.3B	—
Q4 24	$5.3B	$6.3B	—
Q1 25	$3.2B	$5.0B	—
Q2 25	$3.5B	$5.8B	—
Q3 25	$3.7B	$5.9B	—
Q4 25	$4.3B	—	$6.8B
Q1 26	$3.5B	—	$6.0B
Q1 26	$3.5B	—	$6.0B

Revenue Segments

Quarter	Consumer	Medical Devices	Pharmaceutical	Innovative Medicine	Med Tech
Q1 22	$3.6B	$7.0B	$12.9B	—	—
Q2 22	$3.8B	$6.9B	$13.3B	—	—
Q1 24	—	—	—	$13.6B	$7.8B
Q2 24	—	—	—	$14.5B	$8.0B
Q3 24	—	—	—	$14.6B	$7.9B
Q4 24	—	—	—	$14.3B	$8.2B
Q1 25	—	—	—	$13.9B	$8.0B
Q2 25	—	—	—	$15.2B	$8.5B
Q3 25	—	—	—	$15.6B	$8.4B
Q4 25	—	—	—	$15.8B	$8.8B

Revenue by Geography

Quarter	Asia-Pacific, Africa	Europe	United States	Western Hemisphere, excluding U.S.
Q1 22	$4.5B	$6.0B	$11.4B	$1.5B
Q2 22	$4.2B	$6.1B	$12.2B	$1.5B
Q1 24	$3.4B	$5.2B	$11.6B	$1.2B
Q2 24	$3.5B	$5.2B	$12.6B	$1.2B
Q3 24	$3.5B	$4.9B	$12.9B	$1.2B
Q4 24	$3.3B	$4.9B	$13.2B	$1.1B
Q1 25	$3.3B	$5.1B	$12.3B	$1.2B
Q2 25	$3.6B	$5.4B	$13.5B	$1.2B

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$11.0B	$21.6B	$32.6B
Q3 22	$11.4B	$22.7B	$34.1B
Q4 22	$12.9B	$9.4B	$22.3B
Q1 23	$19.2B	$5.4B	$24.6B
Q2 23	$21.2B	$7.3B	$28.5B
Q3 23	$19.7B	$3.8B	$23.5B
Q4 23	$21.9B	$1.1B	$22.9B
Q1 24	$25.5B	$745M	$26.2B
Q2 24	$24.9B	$597M	$25.5B
Q3 24	$20.0B	$317M	$20.3B
Q4 24	$24.1B	$417M	$24.5B
Q1 25	$38.5B	$307M	$38.8B
Q2 25	$18.6B	$303M	$18.9B
Q3 25	$18.2B	$331M	$18.6B
Q4 25	$19.7B	$393M	$20.1B
Q1 26	$21.7B	$363M	$22.1B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	2.67B	-0.1%	-0.2%
Q2 22	2.67B	+0.1%	-0.1%
Q3 22	2.66B	-0.2%	-0.5%
Q4 22	2.66B	+0.1%	-0.2%
Q1 23	2.61B	-2.2%	-2.3%
Q2 23	2.63B	+0.8%	-1.6%
Q1 24	2.43B	-7.4%	-8.7%
Q2 24	2.42B	-0.3%	-9.1%
Q3 24	2.43B	+0.2%	-6.8%
Q4 24	2.43B	-0.0%	-7.6%
Q1 25	2.42B	-0.1%	-0.3%
Q2 25	2.42B	-0.2%	-0.1%
Q3 25	2.43B	+0.4%	+0.0%
Q4 25	2.44B	+0.4%	+0.5%
Q1 26	2.45B	0.0%	+1.1%
Q1 26	2.45B	0.0%	+1.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$165.3K	142K
Q2 22	$169.5K	142K
Q3 22	$141.1K	142K
Q4 22	$167.3K	142K
Q1 23	$136.8K	153K
Q2 23	$140.9K	153K
Q1 24	$162.1K	132K
Q2 24	$170.2K	132K
Q3 24	$170.4K	132K
Q4 24	$163.1K	138K
Q1 25	$158.5K	138K
Q2 25	$171.9K	138K
Q3 25	$173.7K	138K
Q4 25	$177.7K	138K
Q1 26	$174.1K	138K
Q1 26	$174.1K	138K

Revenue / Employee